Inspire Medical Systems, Inc.

As of October 24, 2025, Inspire Medical Systems, Inc. has shifted to a bearish trend, supported by negative signals from moving averages, KST, and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -58.18%.

As of October 24, 2025, Inspire Medical Systems, Inc. has a bearish technical outlook, supported by bearish moving averages and Bollinger Bands, despite some short-term strength indicated by the MACD.

As of October 24, 2025, Inspire Medical Systems, Inc. is in a bearish trend, indicated by negative signals from moving averages and KST, with a year-to-date return of -58.18% compared to the S&P 500's 15.47%.

As of October 17, 2025, Inspire Medical Systems, Inc. is considered overvalued with a valuation grade of fair, reflected by a high P/E ratio of 60 and significant underperformance of -60.44% over the past year compared to the S&P 500's 14.08%.

As of October 17, 2025, Inspire Medical Systems, Inc. is considered overvalued with a P/E ratio of 60, significantly higher than the peer average of 43.22, and has underperformed the S&P 500 with a year-to-date return of -57.92%.

As of October 17, 2025, Inspire Medical Systems, Inc. is considered overvalued with a high P/E ratio of 60 compared to its peers, a low PEG ratio of 0.12, and a significant year-to-date underperformance of -57.92% against the S&P 500's 13.30% return, leading to a valuation grade downgrade from attractive to fair.

As of May 14, 2025, Inspire Medical Systems, Inc. is in a bearish trend with weak momentum indicators, underperforming the S&P 500 significantly with a year-to-date return of -55.01%.

As of September 3, 2025, Inspire Medical Systems, Inc. is fairly valued despite a high P/E ratio of 60, a low PEG ratio of 0.12 indicating growth potential, and a year-to-date stock performance lagging at -55.01% compared to the S&P 500's 12.22%.

As of May 29, 2025, Inspire Medical Systems, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 60, an EV to EBITDA of 62.23, and a PEG ratio of 0.12, indicating strong growth potential despite a year-to-date return of -29.88%.

As of May 14, 2025, the technical trend is bearish, supported by negative signals from the MACD, Bollinger Bands, and moving averages, despite some mixed indicators like the KST and Dow Theory.

As of March 2022, the management team of Inspire Medical Systems, Inc. includes Marilyn Nelson (Independent Chairman), Timothy Herbert (CEO), and directors Shelley Broader, Georgia Garinois-Melenikiotou, Gary Ellis, Jerry Griffin, and Shawn McCormick. They are responsible for the company's strategic direction and operations.

Inspire Medical Systems, Inc. is a mid-cap medical technology company that develops minimally invasive solutions for obstructive sleep apnea. As of March 2025, it reported net sales of $201 million and a net profit of $3 million.

As of Jun 18, Inspire Medical Systems, Inc. has a market capitalization of $3.75 billion, with net sales of $840.11 million and a net profit of $66.50 million over the latest four quarters. The company's shareholder's funds are $689.70 million, and total assets amount to $808.38 million.